MedTrace Logo

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

NCT00751348 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475

Last updated 2018-06-08

Study results available
· View outcomes & findings →

Summary

This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.

Conditions

Interventions

BIOLOGICAL

PriorixTM

Subcutaneous administration in left upper arm

BIOLOGICAL

VarilrixTM

Subcutaneous administration in right upper arm

BIOLOGICAL

Priorix-Tetra®

Subcutaneous injection in left upper arm

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
11 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-01
Primary Completion
2010-05-27
Completion
2010-05-27

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751348 on ClinicalTrials.gov